Loading news...
Guru Stock PicksFairholme Fund has made the following transactions:Reduce in JOE by 0.23%David Tepper has made the following transactions:Reduce in WHR by 18.41
Moderna is initiated at a buy rating, as multiyear growth drivers and robust 2026 guidance signal a turnaround. mNEXSPIKE approvals, flu and combo vaccines, and mRNA therapeutics expansion underpin Moderna's growth prospects for the coming years. Revenue declines are slowing, cost controls are effective, and losses are narrowing, with 2026 guidance targeting up to 10% revenue growth.
Major stock indexes jumped Wednesday, a day after they fell but finished well above early lows, as Middle East fighting entered its fifth day.
Moderna, Inc. settles its LNP patent dispute with Arbutus and Genevant for a $950 million upfront payment, eliminating a major litigation overhang. MRNA secures royalty-free access to critical LNP technology, ensuring freedom to operate for its infectious disease and vaccine pipeline, including future combo vaccines. The settlement preserves MRNA's strong balance sheet, with projected 2026 liquidity of $5.4–$5.9 billion, supporting pipeline expansion and breakeven target by 2028.
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock added almost 9% after it was announced that the drugmaker has agreed to pay up to $2.25 billion to settle a global patent infringement lawsuit brought by Arbutus Biopharma and Genevant Sciences over the use of lipid nanoparticle (LNP) delivery technology in its COVID-19 and RSV vaccines. The settlement resolves all US and international enforcement actions related to Moderna's use of Arbutus' and Genevant's LNP technology in Spikevax, its COVID-19 vaccine, and mRESVIA, its RSV vaccine.
Walmart is expertly navigating a challenging retail environment while continuing to grow its dividend. Moderna has a promising candidate that could hit the market in the near future.
Stocks are in rally mode today, as developments in the Middle East indicate oil price relief and an end to the conflict
Two stocks are standing out in premarket trading this Wednesday morning. Moderna (Nasdaq: MRNA) is up 8.9% and Ross Stores (Nasdaq: ROSS) is up 6.6% as of 8:00 AM ET, each moving on a distinct catalyst.
Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its pipeline.
Moderna Inc. (NASDAQ: MRNA) shares are up during Wednesday's premarket session following a settlement agreement with Arbutus Biopharma Corporation (NASDAQ: ABUS) and Roivant Inc.'s (NASDAQ: ROIV) Genevant Sciences.
Stock News Wall Street whipsawed by Mideast turmoil: The SPDR S&P 500 ETF Trust (SPY) fell Tuesday, then futures steadied as oil volatility and safeâhaven flo
The company settles to resove patent litigation related to its Covid-19 vaccine, removing an overhang for shares.
Moderna settled a yearslong patent dispute with Arbutus Biopharma and a subsidiary of Roivant Sciences. The news sent Moderna shares jumping.
The deal would provide ‘certainty' for Moderna's vaccine portfolio.
Moderna shares are rising in Tuesday's after-hours session after the company announced it reached a settlement agreement.
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in Q1 2026 District Court's Section 1498 decision to be appealed to the Federal Circuit Court of Appeals with potential additional payment contingent on the outcome; no accrual recorded for potential additional payment as loss is not considered probable 2026 year-end cash and cash equivalents now expected to be in the range of $4.5 - $5.0 billion CAMBRIDGE, MA / ACCESS Newswire / March 3, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has entered into a settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH resolving all litigation worldwide, including between the parties in the U.S. District Court for the District of Delaware. The settlement resolves all worldwide Arbutus/Genevant litigation related to Spikevax® and mRESVIA® and provides certainty going forward for Moderna's full infectious disease portfolio, including mNEXSPIKE®, mCOMBRIAX® and its future vaccine pipeline, with no future royalties owed.